Paxlovid more effective in older, vaccinated COVID-19 patients, research shows
Researchers looked at data for more than 180,000 patients in Israel who had tested positive for COVID-19.
Paxlovid, a combination of nirmatrelvir and ritonavir, works by inhibiting a protease required for viral replication
Shutterstock.com
The COVID-19 antiviral Paxlovid (nirmatrelvir + ritonavir; Pfizer) is associated with a 46% reduced risk of progression to severe COVID-19 or mortality, regardless of vaccination status, study results published in Clinical Infectious Diseases have suggested.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
